Korro Bio, Inc. · 13 hours ago
Senior Manager, Clinical Operations
Korro Bio is a biopharmaceutical company focused on developing innovative genetic medicines. The Senior Manager of Clinical Operations will lead early phase clinical trials, ensuring compliance and collaboration with stakeholders, while optimizing trial design and execution.
BiotechnologyHealth CarePharmaceutical
Responsibilities
Plan, drive and oversee all aspects of multi-center global clinical trials in compliance with GCPs, SOPs, and within designated program budgets and timelines in close collaborations with key stakeholders and Clinical Research Organizations (CROs)
Drive implementation of clinical operational strategy for successful delivery of assigned clinical studies
Use operational and therapeutic expertise to optimize trial design and execution and collaborate with the study team to accelerate clinical trial timelines
Provide oversight and management for all relevant CROs and vendors including contracting and clinical budgets; develop contingency plans for clinical trials
Coordinate and lead study team meetings and update the Program Team on timelines and milestones for the study
Contribute to the development of study documentation including protocol review, creating study plans, ICFs, and designing CRFs
Contribute to CRO/vendors identification, qualification and selection processes as applicable
Participate in study site selection; review and update site specific consent forms; track patient accrual and study progress via standard reports; assure patient eligibility; document protocol deviations/violations; and manage adverse event reporting
Oversee clinical monitoring from site qualification to site closure visits and assure integrity of clinical data with respect to accuracy, accountability and documentation through review of case report forms, source documents, and medical records. Evaluate and analyze clinical data
Oversee high quality implementation, execution and delivery of studies by CROs in alignment with timeline and budget plan
Establish an open team culture defined by transparent communication, clear goal setting, and risk-based oversight
Ensure compliance with internal policies and procedures, GCPs, and applicable regulations; ensure inspection readiness
Oversee Vendor Contracts and Clinical Study Budget, report progress to finance team
Provide input to Clinical Study Reports and Investigator Brochures, including data cleaning, listing review, and report writing
Oversee TMF management and review TMF documentation as necessary
Limited travel possible to field sites to supervise and/or monitor clinical studies (<25%)
Qualification
Required
Bachelor's Degree; Life Sciences preferred. Advanced degree desirable
8+ years of relevant clinical development and operations experience, in clinical operations leadership roles, leading global clinical studies/programs, with track records of initiating and delivering early phase trials
Experience in rare diseases and early phase studies (including FIH studies) is highly desirable
Strong leadership skills driving large cross functional teams
Deep knowledge of global regulatory and compliance requirements for clinical research, local country requirements and ICH GCP, including experience with global regulatory inspections
Excellent critical and strategic thinking, with strong ability to understand the big picture as well as the important details that may impact the big picture
Global clinical operations & development experience across therapeutic areas with demonstrated ability to rapidly learn new indications
Excellent communicator and influencer, able to persuasively convey ideas and data, verbally and in writing
Benefits
Medical
Dental
Vision
401(k) retirement plan
Life insurance
A dependent care flexible spending account
A Company-funded health savings account
Free parking
Company
Korro Bio, Inc.
Korro Bio was founded to turn extraordinary scientific insights into life-altering new treatments for patients.
Funding
Current Stage
Public CompanyTotal Funding
$277.5MKey Investors
Deep Track CapitalEventideWu Capital
2024-04-18Post Ipo Equity· $70M
2023-11-06IPO
2022-01-05Series B· $116M
Recent News
2026-01-09
New Enterprise Associates
2026-01-05
Genetic Engineering News
2025-11-19
Company data provided by crunchbase